Who’s In Control? Thoratec, Investigators Discuss Access To NIH-Funded Data
This article was originally published in The Gray Sheet
Executive Summary
Thoratec is in negotiations with NIH to restrict access to control group data from the REMATCH randomized trial of the HeartMate VE upon the study's completion
You may also be interested in...
FDA Will Relax Premarket Requirements To Enable LVAD Randomized Trials
Randomized, controlled trials supporting PMAs for left-ventricular assist devices as destination therapy should compare the investigational device with an already approved LVAD, according to FDA
FDA Will Relax Premarket Requirements To Enable LVAD Randomized Trials
Randomized, controlled trials supporting PMAs for left-ventricular assist devices as destination therapy should compare the investigational device with an already approved LVAD, according to FDA
LVAD Developers Look To Medicare Coverage Decision To Offset Trial Costs
Launch of clinical trials for the DeBakey LVAD as destination therapy for end-stage heart failure patients is contingent on CMS issuing a national coverage decision for the expanded claim, MicroMed maintains